Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study
复制标题
DOI：
10.1200/jco.2002.07.089
复制
发表时间：
2002-04-01
影响因子：
45.3
通讯作者：
Wong, J
中科院分区：
文献类型：
--
作者：
Poon, RTP;Ng, IOL;Wong, J
目的：本研究前瞻性研究了100例肝细胞癌（HCC）切除术后肿瘤微血管密度（MVD）与临床病理特征及术后复发的关系。患者与方法：采用免疫组化CD 34（MVD-CD 34）和血管性血友病因子（MVD-vWF）染色，应用计算机图像分析仪检测100例HCC切除术后肿瘤MVD。结果：平均肿瘤MVD-CD 34（236/0.74 mm（2））高于平均肿瘤MVD-vWF（87/0.74 mm（2））（P <0.001）。通过多元回归分析，肿瘤大小是唯一与肿瘤MVD-CD 34显著相关的病理特征。小于或等于5 cm的HCC中位MVD CD 34为316/0.74 mm（2）（n = 46），大于5 cm的HCC中位MVD CD 34为146/0.74 mm（2）（n = 54）（P <0.001）。在HCC小于或等于5 cm的患者中，MVD-CD 34高于中位数的患者的无病生存率（3年，13%）低于MVD-CD 34较低的患者（3年，74%）（P = 0.002）。多因素分析显示，肿瘤MVD-CD 34是预测小于或等于5 cm HCC患者无病生存率的唯一显著因素。对于大于5 cm的HCC，MVD-CD 34没有显著的预后影响。MVD-vWF对小于或等于5 cm或大于5 cm的肝癌的无病生存期没有显着的预后影响。结论：本研究表明，高MVD-CD 34可以预测肝癌患者的早期切除后复发小于或等于5 cm，因此，可能是该患者子集的一种新的预后标志物。(C)2002年，美国临床肿瘤学会。
Purpose: This study prospectively evaluated the correlation of tumor microvessel density (MVD) with clinicopathologic features and postoperative recurrence in patients undergoing resection of hepatocellular carcinoma (HCC).Patients and Methods: Tumor MVD was assessed in 100 patients with resection of HCC using a computer image analyzer after immunostaining for CD34 (MVD-CD34) and von Willebrand factor (MVD-vWF), respectively. Patients were prospectively followed for recurrence.Results: Mean tumor MVD-CD34 (236/0.74 mm(2)) was higher than mean tumor MVD-vWF (87/0.74 mm(2)) (P < .001). By multiple regression analysis, tumor size was the only pathologic feature significantly related to tumor MVD-CD34. The median MVD-CD34 was 316/0.74 mm(2) in HCCs less than or equal to 5 cm (n = 46) and 146/0.74 mm(2) in HCCs more than 5 cm (n = 54) (P < .001). Among patients with HCCs less than or equal to 5 cm, those with higher than median MVD-CD34 had worse disease-free survival (at 3 years, 13%) than those with a lower MVD-CD34 (at 3 year, 74%) (P = .002). Multivariate analysis showed that tumor MVD-CD34 was the only significant factor predictive of disease-free survival in patients with HCC less than or equal to 5 cm. For HCCs more than 5 cm, MVD-CD34 did not have a significant prognostic influence. MVD-vWF did not have a significant prognostic influence on disease-free survival in either HCCs less than or equal to 5 cm or more than 5 cm.Conclusion: This study shows that a high MVD-CD34 was predictive of early postresection recurrence in patients with HCCs less than or equal to 5 cm and, therefore, may be a novel prognostic marker in this subset of patients. (C) 2002 by American Society of Clinical Oncology.